Pyxis Oncology, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Pyxis Oncology announced positive updated Phase 1 monotherapy data for MICVO (micvotabart pelidotin) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) as of August 18, 2026. In 33 efficacy-evaluable patients dosed at 5.4 mg/kg Q3W with dose cap: confirmed objective response rate 36% (12/33), disease control rate 94% (31/33), median progression-free survival 6.2 months (95% CI 4.8–8.8), and 12-month overall survival probability 79% (95% CI 58.1–90.3). No new safety signals observed; dose cap reduced adverse events in high body-weight patients. Company plans Phase 3 'Headliner' trial initiation in mid-2027; FDA/EMA End of Phase 2 meeting expected Q1 2027.
Why this rating
Clinical-stage company ($64M market cap). Lead program showing strong efficacy vs. historical controls and de-risking path to pivotal trial. Material near-term value driver; however, Phase 3 success uncertain.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.10 ▼ 20.31% | at our read · unknown $3.89 | +10 min · unknown $3.89 ▲ 0.00% | +30 min · unknown $3.89 ▲ 0.00% | +1 hr · unknown $3.89 ▲ 0.00% | +4 hrs pending |
The stock had already moved +25.48% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.